Wainua is a drug owned by Astrazeneca Ab. It is protected by 3 US drug patents filed in 2026 out of which none have expired yet. Wainua's patents will be open to challenges from 22 December, 2027. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 25, 2034. Details of Wainua's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US10683499 | Compositions and methods for modulating TTR expression |
Aug, 2034
(8 years from now) | Active |
| US9181549 | Conjugated antisense compounds and their use |
May, 2034
(7 years from now) | Active |
| US9127276 | Conjugated antisense compounds and their use |
May, 2034
(7 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but
Wainua is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Wainua's family patents as well as insights into
ongoing legal events
on those patents.
Wainua's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Wainua's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 25, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Wainua Generics:
There are no approved generic versions for Wainua as of now.
Alternative Brands for Wainua
There are several other brand drugs in the same treatment category and using the same active ingredient (Eplontersen Sodium) as Wainua. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Alnylam Pharms Inc |
| |||
| Astrazeneca Ab |
| |||
About Wainua
Wainua is a drug owned by Astrazeneca Ab. Wainua uses Eplontersen Sodium as an active ingredient. Wainua was launched by Astrazeneca in 2026.
Approval Date:
Wainua was approved by FDA for market use on 15 April, 2026.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Wainua is 15 April, 2026, its NCE-1 date is estimated to be 22 December, 2027.
Active Ingredient:
Wainua uses Eplontersen Sodium as the active ingredient. Check out other Drugs and Companies using Eplontersen Sodium ingredient
Dosage:
Wainua is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML) | SOLUTION | Prescription | SUBCUTANEOUS |